"The global spread of carbapenem-resistant Enterobacterales (CRE) has been fostered by the lack of preemptive screening of patients in healthcare facilities that could prevent patient-to-patient transmission."
Carbapenem-resistant Enterobacterales (CRE) have become a public health threat worldwide.
There are three distinct mechanisms by which Enterobacterales have become resistant to carbapenems: enzyme production, efflux pumps, and porin mutations, but of these enzyme production is the main mechanisms of resistance. The enzyme produced can determine treatment of infection; therefore proper, rapid identification of the enzyme can be a key factor to mitigating prolonged therapy and determining the correct carbapenem antibiotic for treatment. Hardy Diagnostics is proud to offer a new tool in the fight against carbapenem resistance:
PREVENTION WORKS. According to the CDC's 2019 Antibiotic Resistance Threat Report, U.S CRE cases are stable. This observation speaks to the success of the currently implemented infection control and other preventative strategies; however, CONTINUED ACTION IS NEEDED.
Introducing NG-Test® CARBA 5:
Rapid detection and differentiation of the five most common carbapenemases produced by Enterobacteriaceae and Pseudomonas aeruginosa resistance mechanisms.
The only rapid, multiplex, phenotypic test capable of detecting KPC, OXA-48-like, VIM, IMP, and NDM carbapenemases produced by Enterobacterales and P. aeruginosa.
The cost per test versus PCR makes it extremely economical.
Easy to implement
NG-Test® CARBA 5 naturally fits into your workflows and requires no specialized training, unlike molecular tests.
With NG-Test® CARBA 5, you don’t need to guess. Simply perform the test from bacterial culture and in 15 minutes you’ll save more than money; you’ll be saving lives.
PCR tests will only detect the gene, but is the gene expressing? That’s what counts. NG-Test® CARBA 5 provides rapid detection of resistant phenotypes which allows you to fast-track infection control measures with accuracy.
Patient care is the highest priority when dealing with infection control and resistant bacteria. Every minute spent searching is a minute delaying accurate treatment.
A "LINE" means an ENZYME!
HardyCHROM™ CRE is a selective and differential chromogenic agar medium intended for the qualitative and presumptive detection from stool specimens of Escherichia coli that are non-susceptible to carbapenems as pink colonies and KES (Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Enterobacter cloacae complex, and Serratia marcescens) that are non-susceptible to carbapenems as blue colonies. HardyCHROM™ CRE is intended as an aid in the detection, identification of colonization and control of these bacteria in a healthcare setting. HardyCHROM™ CRE is not intended to diagnose infection or guide therapy. Results can be interpreted after incubation for 18-24 hours. Subculture to non-selective medium is required for confirming identification, antimicrobial susceptibility testing and epidemiological typing.
The customer service department at Hardy Diagnostics is phenomenal. If I have a deadline to beat, I do not even bother with my other vendors. The CSRs are always available, knowledgeable, and provide a positive experience over the phone and through emails. I have never been let down by Hardy Diagnostics. If I have a question regarding shipping, ordering, technical specifications, or billing I am always given Grade A attention.
Overall, I recommend your company to everyone, and your website is very user friendly. Your pricing is very competitive and I can always get a discounted price on items we purchase.